診療と新薬 2023；60（12）：753-764

微電流とLEDライトの働きをもつ美容機器と薬用育毛剤を12週間併用した際の効果

Shinryo to Shinyaku （Med Cons New-Remed）2023；60（12）：753-764

Effects of Using a Beauty Device with Microcurrent and LED Light in Combination with a Medicated Hair Growth Product for 12 WeeksEffects of Using a Beauty Device with Microcurrent and LED Light in Combination with a Medicated Hair Growth Product for 12 Weeks

PDF：324 KB

左のアイコンをクリックすると、PDF が表示されます。
When you click on the icon to the left, you will see the PDF.

診療と新薬 2023；60（12）：765-771

Shinryo to Shinyaku （Med Cons New-Remed）2023；60（12）：765-771

The Safety Assessment of Stable Type Neutral Vitamin C Derivative (MIRAVC)

Masahiko NAKANO 1)，Atsuyoshi MURAKAMI 2)，Akio YAMAMOTO 1)／Nobuo KUBO 3)

1) Dr's Choice Co., Ltd., Tokyo Japan，2) The Information of Biomedical Science and Ultimate Technology Co., Ltd., Tokyo Japan，3) The Kitahama TOWER Jibiinkoka Hifuka Clinic, Osaka, Japan

Objective: To examine the safety of a newly developed ascorbic acid derivative based on ascorbyl glucoside (MIRAVC), as a raw material for topical preparations.
Methods: A primary skin irritation test, an Ames test, a human patch test, a human stinging test, and an ocular mucosal irritation test were conducted to evaluate the safety of this compound. In addition, using a three-dimensional cultured skin model, living skin equivalent model (LSE-high), we also evaluated transdermal absorption using a Franz-type diffusion cell system.
Results: Together with the test results of stability and transdermal absorption, all safety tests showed negative results, and no events were observed that would be of concern when used topically by humans.

Key words: Safety assessment, Ascorbyl glucoside, Skin permeability, Topical

Shinryo to Shinyaku （Med Cons New-Remed）2023；60（12）：765-771

The Safety Assessment of Stable Type Neutral Vitamin C Derivative (MIRAVC)

PDF：316 KB

左のアイコンをクリックすると、PDF が表示されます。
When you click on the icon to the left, you will see the PDF.

診療と新薬 2023；60（12）：772-773

DrugFlag■当院におけるイメグリミン処方時の工夫：より安全に，効果的に使用するために

藤原正純

西条中央病院 糖尿病内科 健康管理センター長

Shinryo to Shinyaku （Med Cons New-Remed）2023；60（12）：772-773

How to Prescribe Imeglimin to TYPE 2-Diabetes Patients in Our Hospital

Masazumi FUJIWARA

Department of Diabetology and Health Care Centre Administrator, Saijo Central Hospital

ミトコンドリアに作用する新しい機序により低血糖リスクが少ない2型糖尿病治療剤イメグリミンは，メトホルミン（BG：ビグアナイド薬）と骨格が類似しており，ビグアナイド製剤と併用の際は特に消化器症状が出現しやすい。今回，イメグリミン処方に際しての当院の工夫を紹介させて頂きたい。

キーワード：2型糖尿病，イメグリミン，ビグアナイド薬，消化器症状

診療と新薬 2023；60（12）：772-773

DrugFlag■当院におけるイメグリミン処方時の工夫：より安全に，効果的に使用するために

藤原正純

西条中央病院 糖尿病内科 健康管理センター長

Shinryo to Shinyaku （Med Cons New-Remed）2023；60（12）：772-773

How to Prescribe Imeglimin to TYPE 2-Diabetes Patients in Our Hospital

Masazumi FUJIWARA

Department of Diabetology and Health Care Centre Administrator, Saijo Central Hospital

Imeglimin is similar structure to metformin but new type of oral medication for diabetes. To type2 diabetes patients taking metformin, add on Imeglimin therapy tends to occur digestive symptones including nausea, vomiting, poor appetite, constipation, diarrhea and so on. In Our hospital, patients take Imeglimin step by step 500 mg (1 tablet) gradually for 1 to 3 months. When they have the above uncomfortable symptons, they decrease Imeglimin dose by themselves to be better comfortable conditions. This metods in our hospital decreas the digestive symptones of Imeglimin.

Key words: type 2 diabetes, imeglimin, biguanide, digestive symptones

診療と新薬 2023；60（12）：772-773

DrugFlag■当院におけるイメグリミン処方時の工夫：より安全に，効果的に使用するために

Shinryo to Shinyaku （Med Cons New-Remed）2023；60（12）：772-773

How to Prescribe Imeglimin to TYPE 2-Diabetes Patients in Our Hospital

PDF：299 KB

左のアイコンをクリックすると、PDF が表示されます。
When you click on the icon to the left, you will see the PDF.